Technological advances in high throughput biology, imaging, data management and tissue banking mean that there has never been greater capacity to understand the pathophysiology of numerous diseases and chronic health conditions at the molecular level.
Those same advances enable better health management in terms of disease detection and therapeutic management. With the increased capability to address such questions also comes greater scrutiny by regulators such as the FDA now requesting data that further validates the mode of action, stratifies patients and that supports the case for reimbursement.
Applying these tools to the discovery, development, use and regulation of new medicines will lead us ever closer to the goal of truly personalised medicine.
Speakers at this next Life Science Leadership Series event will present some of the leading edge technologies in this field, along with case studies of how they are being used in the development of new therapeutic strategies targeting better outcomes for patients, greater efficiency for the developers of innovative medicines and better use of constrained budgets by healthcare providers.